Skip to main content
SpringerLink
Log in

When Should Surgery Be Performed for the First-Line Treatment of Advanced Ovarian Cancer?

  • Chapter
  • First Online:
Controversies in the Management of Gynecological Cancers

  • 1007 Accesses

Abstract

Seventy-five percent of patients diagnosed with ovarian cancer still present with advanced stage disease (FIGO stages III and IV). The standard management for these patients has always been up-front surgery, with the aim of achieving complete macroscopic removal of tumor followed by chemotherapy. In 2010, the results from a large phase III randomized study performed by the EORTC suggested no difference in survival whether the chemotherapy was given following the surgery or as neoadjuvant treatment prior to surgery. This review will tease out the pros and cons of either management strategy based on the current evidence available and make recommendations for future research in the area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  CAS  PubMed  Google Scholar 

  2. Griffiths CT. Surgical resection of tumour bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.

    CAS  PubMed  Google Scholar 

  3. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25(20):2873–83.

    Article  PubMed  Google Scholar 

  4. Skipper HE, Schabel Jr FM, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54(6):431–50.

    CAS  PubMed  Google Scholar 

  5. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):269–74.

    Article  CAS  PubMed  Google Scholar 

  6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.

    Article  PubMed  Google Scholar 

  7. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115(6):1234–44.

    Article  PubMed  Google Scholar 

  8. Winter III WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25(24):3621–7.

    Article  PubMed  Google Scholar 

  9. Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(1):83–9.

    Article  PubMed  Google Scholar 

  10. Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012;22(3):380–5.

    Article  PubMed  Google Scholar 

  11. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–5.

    Article  PubMed  Google Scholar 

  12. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol. 2009;27(9):1419–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005;23(34):8802–11.

    Article  PubMed  Google Scholar 

  14. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47(2):159–66.

    Article  CAS  PubMed  Google Scholar 

  15. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332(10):629–34.

    Article  PubMed  Google Scholar 

  16. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009;112(2):422–36.

    Article  PubMed  Google Scholar 

  17. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 1999;106(11):1130–6.

    Article  CAS  PubMed  Google Scholar 

  18. Trope C, Kaern J. Primary surgery for ovarian cancer. Eur J Surg Oncol. 2006;32(8):844–52.

    Article  CAS  PubMed  Google Scholar 

  19. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85.

    Article  PubMed  Google Scholar 

  20. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.

    Article  PubMed  Google Scholar 

  21. Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;4, CD007697.

    PubMed  Google Scholar 

  22. Du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer. 2012;22(2):182–5.

    Article  PubMed  Google Scholar 

  23. Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol. 2011;122(1):100–6.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Verleye L, Vergote I, van der Zee AG. Patterns of care in surgery for ovarian cancer in Europe. Eur J Surg Oncol. 2010;36 Suppl 1:S108–14.

    Article  PubMed  Google Scholar 

  25. du Bois A, Harter P, editors. Understanding and optimizing the potential role of surgical debulking in advanced epithelial ovarian cancer. In: American Society of Clinical Oncology annual meeting, Chicago, 4–8 Jun 2010.

    Google Scholar 

  26. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–6.

    Article  CAS  PubMed  Google Scholar 

  27. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16(8):2315–20.

    Article  PubMed  Google Scholar 

  28. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

    Article  CAS  PubMed  Google Scholar 

  29. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    Article  CAS  PubMed  Google Scholar 

  30. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–8.

    Article  CAS  PubMed  Google Scholar 

  31. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener HC, Lopes T, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. J Clin Oncol (Meeting Abstracts). 2013;31(15_suppl):5500.

    Google Scholar 

  32. Fagö-Olsen CL, Ottesen B, Kehlet H, Markauskas A, Mosgaard BJ, Ottosen C, et al. Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences. Dan Med J [Serial on the Internet]. 2012;59(8):A4477.

    Google Scholar 

  33. Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol. 2012;24:1–6.

    Article  Google Scholar 

  34. Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol. 2011;29(31):4073–5.

    Article  CAS  PubMed  Google Scholar 

  35. Vergote I, Trope CG, Amant F, Ehlen T, Reed NS, Casado A. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol. 2011;29(31):4076–8.

    Article  CAS  PubMed  Google Scholar 

  36. Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol. 2013;128(1):6–11.

    Article  PubMed  Google Scholar 

  37. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120(1):23–8.

    Article  PubMed  Google Scholar 

  38. Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol. 2011;118(3):537–47.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Neugut AI, et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2011;123(3):467–73.

    Article  PubMed  Google Scholar 

  40. Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012;19(3):959–65.

    Article  PubMed  Google Scholar 

  41. Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol. 2011;123(3):461–6.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer. 2010;20 Suppl 1:S1–11.

    Article  PubMed  Google Scholar 

  43. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.

    Article  CAS  PubMed  Google Scholar 

  44. Bear HD, Tang G, Rastogi P, Geyer Jr CE, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309.

    Article  Google Scholar 

  46. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842–7.

    Article  PubMed  Google Scholar 

  47. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862–70.

    Article  CAS  PubMed  Google Scholar 

  48. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol. 2013;24(3):702–9.

    Article  CAS  PubMed  Google Scholar 

  49. Ledermann JA. Primary chemotherapy: the future for the management of advanced ovarian cancer? Int J Gynecol Cancer. 2010;20(11 Suppl 2):S17–9.

    Article  PubMed  Google Scholar 

  50. Glimelius B, Lahn M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol. 2011;22:1717–25.

    Article  CAS  PubMed  Google Scholar 

  51. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189(4):1120–7.

    Article  PubMed  Google Scholar 

  52. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.

    Article  CAS  PubMed  Google Scholar 

  53. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;8, CD007565.

    PubMed  Google Scholar 

  54. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351(24):2489–97.

    Article  CAS  PubMed  Google Scholar 

  55. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10–4.

    Article  PubMed  Google Scholar 

  56. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384–9.

    Article  PubMed  Google Scholar 

  57. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2008;108(2):271–5.

    Article  PubMed  Google Scholar 

  58. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 2005;96(2):301–6.

    Article  PubMed  Google Scholar 

  59. Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100(3):455–61.

    Article  PubMed  Google Scholar 

  60. Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa AC, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol. 2005;96(3):729–35.

    Article  PubMed  Google Scholar 

  61. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199(6):642.e1–6.

    Google Scholar 

  62. Rutten MJ, Gaarenstroom KN, Van Gorp T, van Meurs HS, Arts HJ, Bossuyt PM, et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. BMC Cancer. 2012;12:31.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynaecology Oncology, King Edward Memorial Hospital, 374 Bagot Road, Perth, WA, 6008, Australia

    Ganendra Raj K. A. Mohan MBBS, MRCOG, FRANZCOG, CGO

  2. MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London, WC2B 6NH, UK

    Jane Hook MA, MB, BChir, MRCP

  3. UCL Cancer Institute, University College London, Cancer Research UK and UCL Cancer Trials Centre, 90 Tottenham Court Road, London, W1T 4TJ, UK

    Jonathan A. Ledermann BSc, MD, FRCP

  4. The University of Melbourne, Royal Women’s Hospital, Melbourne, Australia

    Michael A. Quinn MB, ChB, MGO (Melb), MRCP (UK), FRANZCOG, FRCOG, CGO (Professor of Gynaecological Oncology)

Authors
  1. Ganendra Raj K. A. Mohan MBBS, MRCOG, FRANZCOG, CGO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Hook MA, MB, BChir, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan A. Ledermann BSc, MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael A. Quinn MB, ChB, MGO (Melb), MRCP (UK), FRANZCOG, FRCOG, CGO
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ganendra Raj K. A. Mohan MBBS, MRCOG, FRANZCOG, CGO .

Editor information

Editors and Affiliations

  1. UCL Cancer Institute, University College London, London, United Kingdom

    Jonathan A. Ledermann

  2. Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands

    Carien L. Creutzberg

  3. Royal Women’s Hospital, The University of Melbourne, Melbourne, Australia

    Michael A. Quinn

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Mohan, G.R.K.A., Hook, J., Ledermann, J.A., Quinn, M.A. (2014). When Should Surgery Be Performed for the First-Line Treatment of Advanced Ovarian Cancer?. In: Ledermann, J., Creutzberg, C., Quinn, M. (eds) Controversies in the Management of Gynecological Cancers. Springer, London. https://doi.org/10.1007/978-0-85729-910-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-910-9_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-909-3

  • Online ISBN: 978-0-85729-910-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation